A Phase 1 Study of SGN-CD48A in Patients With Relapsed or Refractory Multiple Myeloma
Phase of Trial: Phase I
Latest Information Update: 03 Jan 2019
At a glance
- Drugs SGN-CD48A (Primary)
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Seattle Genetics
- 21 Dec 2018 Prior to protocol amendment SGN-CD48A was given every 3 weeks, now it will be given on Days 1, 8, and 15 of a 28-day cycle.
- 21 Dec 2018 Planned number of patients changed from 75 to 85.
- 21 Dec 2018 Planned End Date changed from 1 Jul 2021 to 1 Dec 2021.